HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

About this update from Halozyme Therapeutics, Inc.

[{"type":"text","content":"SAN DIEGO, April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (\"Halozyme\") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (\"Purchaser\"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ: ATRS) (\"Antares\") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the \"Merger Agreement\").\nThe tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of the Merger Agreement. The closing of the tender offer is subject to certain conditions, including the tender of shares representing at least a majority of the total number of Antares' outstanding shares of common stock, the expiration or termination of the HSR waiting period, and other customary conditions. The transaction is expected to close in the first half of 2022, as previously announced.\nHalozyme filed today with the U.S. Securities and Exchange Commission (the \"SEC\") a tender offer statement on Schedule TO, which includes the terms of the tender offer. Additionally, Antares filed a Schedule 14D-9 with the SEC containing the recommendation of its Board of Directors that Antares stockholders accept the tender offer and tender their shares. The Schedule TO, Schedule 14D-9, related letter of transmittal (together with any amendments or supplements thereto) and other tender offer documents can be obtained free of charge at the website maintained by the SEC at www.sec.gov or by contacting the information agent for the tender offer, D.F. King & Co., Inc., as described in the tender offer documents.\nAbout HalozymeHalozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution...

More updates from Halozyme Therapeutics, Inc.